Home > Resources > Whitepapers > Pharma & Biotech 2017 – Review of Outsourced Manufacturing

Pharma & Biotech 2017 – Review of Outsourced Manufacturing

January 26, 2017

This report is an update on the pharmaceutical outsourced manufacturing sector with the last Results’ report published in 2013. By 2015, the global Pharmaceutical market reached $1.11 trillion and is expected to continue growing at approx. 5.5% per annum. Our analysis estimates that the total outsourced manufacturing market reached $71.5bn in 2015 and is growing at 6.6%2. The sector’s faster growth above the pharmaceutical industry is helped by the anticipated transition to more outsourcing, as well as the good growth within particular subsectors.

Spotlight

Will-Pharma

Will-Pharma is a pharmaceutical company whose objective is to place original and quality products on the market.

OTHER WHITEPAPERS

Strengthening Engagement and Influence with Key Decision Makers

whitePaper | January 5, 2023

This report follows up on the jointly hosted Pharmaforce and elandas webinar which took place on July, 12, 2016, featuring contributions from participating industry leaders who formed the expert panel, as well as the live contributions of the audience of healthcare sales and marketing professionals.

The Impact of Rising Generic Drug Prices on the U.S. Drug Supply Chain

whitePaper | April 16, 2020

Over the past two years, the pharmacy industry has seen unprecedented increases in the prices of generic drugs, causing unexpected cost increases for payers and consumers, and spurring an investigation by the United States Congress. High generic drug prices have had an adverse effect on almost everyone in the pharmaceutical supply chain. Consumers face higher co-pays and prices and health plans are dealing with higher drug spend. Physicians are finding the need to prescribe alternative drug therapies while dealing with angry patients.

Choosing the Right Temperature Monitoring Solution

whitePaper | April 24, 2023

Globally, pharmaceutical regulators are becoming attuned to cold chain issues as biologics, vaccines, and other temperature‐sensitive products are commercialized for a global clientele. Many regulators now recommend including temperature monitoring technology in every cold chain shipment.

Manufacturing High-Quality Capsule Products for Pharmaceutical and Nutraceutical Applications

whitePaper | October 25, 2022

To confirm the suitability of empty hard capsules for use in the application of quality-by-design (QbD) in the development and manufacturing of finished pharmaceutical products, the quality target product profile (QTPP) defined by eight critical quality attributes (CQA’s) was examined.

Nanoform Management Presentation

whitePaper | May 24, 2022

Our proprietary nanoforming technologies and services span the full range of drug development from small-molecule nanoparticles to large-molecule biologics.

Drug Solubility and the Need for Speed

whitePaper | March 28, 2023

About 70% of new chemical entities (NCEs) are highly insoluble.1 It’s a fact that troubles small biotechnology companies and other drug manufacturers. Indeed, insoluble drugs present a wide range of challenges during development and, if not addressed, can ultimately render drugs ineffective in patients.